Prelude Therapeutics Inc remains a pre-revenue biotech focused on oncology therapeutics, highlighted by FDA clearance for its Phase I trial candidate PRT12396. The company reported a net loss of approximately $99.5 million and negative operating cash flow of $56.3 million in FY2025, an improvement from prior years. Cash and equivalents of $35.3 million alongside total current assets of about $105.7 million support near-term operations. Strategic partnerships such as the Exclusive Option Agreement with Incyte Corporation provide potential milestone payments and royalties, underpinning growth prospects while the company maintains minimal capital expenditures to prioritize R&D spend.